The association of genetic factors with serum calretinin levels in asbestos-related diseases.

Autor:	Zupanc C; Military Medical Unit-Slovenian Army, Ljubljana, Slovenia.; University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia., Franko A; University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia.; University Medical Centre Ljubljana, Clinical Institute of Occupational Medicine, Ljubljana, Slovenia., Strbac D; University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia.; Institute of Oncology Ljubljana, Ljubljana, Slovenia., Kovac V; University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia.; Institute of Oncology Ljubljana, Ljubljana, Slovenia., Dolzan V; University of Ljubljana, Faculty of Medicine, Institute of Biochemistry and Molecular Genetics, Pharmacogenetics Laboratory, Ljubljana, Slovenia., Goricar K; University of Ljubljana, Faculty of Medicine, Institute of Biochemistry and Molecular Genetics, Pharmacogenetics Laboratory, Ljubljana, Slovenia.
Jazyk:	angličtina
Zdroj:	Radiology and oncology [Radiol Oncol] 2023 Nov 30; Vol. 57 (4), pp. 473-486. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).
DOI:	10.2478/raon-2023-0061
Abstrakt:	Background: Asbestos exposure is associated with different asbestos-related diseases, including malignant mesothelioma (MM). MM diagnosis is confirmed with immunohistochemical analysis of several markers, including calretinin. Increased circulating calretinin was also observed in MM. The aim of the study was to determine if CALB2 polymorphisms or polymorphisms in genes that can regulate calretinin expression are associated with serum calretinin levels or MM susceptibility. Subjects and Methods: The study included 288 MM patients and 616 occupationally asbestos-exposed subjects without MM (153 with asbestosis, 380 with pleural plaques and 83 without asbestos-related disease). Subjects were genotyped for seven polymorphisms in CALB2 , E2F2 , MIR335 , NRF1 and SEPTIN7 genes using competitive allele-specific polymerase chain reaction (PCR). Serum calretinin was determined with ELISA in 545 subjects. Nonparametric tests, logistic regression and receiver operating characteristic (ROC) curve analysis were used for statistical analysis. Results: Carriers of at least one polymorphic CALB2 rs889704 allele had lower calretinin levels (P = 0.036). Carriers of two polymorphic MIR335 rs3807348 alleles had higher calretinin (P = 0.027), while carriers of at least one polymorphic NRF1 rs13241028 allele had lower calretinin levels (P = 0.034) in subjects without MM. Carriers of two polymorphic E2F2 rs2075995 alleles were less likely to develop MM (odds ratio [OR] = 0.64, 95% confidence interval [CI] = 0.43-0.96, P = 0.032), but the association was no longer significant after adjustment for age (P = 0.093). Optimal serum calretinin cut-off values differentiating MM patients from other subjects differed according to CALB2 , NRF1 , E2F2 , and MIR335 genotypes. Conclusions: The results of presented study suggest that genetic variability could influence serum calretinin levels. These findings could contribute to a better understanding of calretinin regulation and potentially to earlier MM diagnosis. (© 2023 Cita Zupanc et al., published by Sciendo.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu